Edwards Lifesciences Corporation (NYSE:EW) – Equities research analysts at Leerink Swann increased their Q2 2018 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a research note issued to investors on Friday. Leerink Swann analyst D. Antalffy now anticipates that the medical research company will post earnings per share of $1.12 for the quarter, up from their prior forecast of $1.01. Leerink Swann also issued estimates for Edwards Lifesciences’ Q3 2018 earnings at $1.00 EPS, Q4 2018 earnings at $1.04 EPS, FY2018 earnings at $4.15 EPS, Q1 2019 earnings at $1.11 EPS, Q2 2019 earnings at $1.23 EPS, Q3 2019 earnings at $1.14 EPS and FY2019 earnings at $4.65 EPS.

Several other equities analysts have also recently issued reports on the stock. BMO Capital Markets restated a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. William Blair restated an “outperform” rating on shares of Edwards Lifesciences in a research report on Monday, August 28th. Royal Bank of Canada restated a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. SunTrust Banks set a $124.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, Morgan Stanley decreased their price target on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. Six investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $126.43.

Shares of Edwards Lifesciences (NYSE EW) traded up $0.15 during midday trading on Monday, reaching $118.18. 1,321,500 shares of the company’s stock traded hands, compared to its average volume of 1,641,517. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. Edwards Lifesciences has a 1 year low of $86.55 and a 1 year high of $121.45. The firm has a market cap of $24,977.50, a PE ratio of 32.69, a P/E/G ratio of 2.11 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. Edwards Lifesciences’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.68 EPS.

Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. lifted its stake in shares of Edwards Lifesciences by 4.6% in the third quarter. Victory Capital Management Inc. now owns 557,773 shares of the medical research company’s stock valued at $60,969,000 after buying an additional 24,399 shares in the last quarter. Korea Investment CORP lifted its stake in shares of Edwards Lifesciences by 144.5% in the third quarter. Korea Investment CORP now owns 355,683 shares of the medical research company’s stock valued at $38,880,000 after buying an additional 210,200 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Edwards Lifesciences by 53.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock valued at $1,418,000 after buying an additional 4,170 shares in the last quarter. Westpac Banking Corp lifted its stake in shares of Edwards Lifesciences by 13.5% in the second quarter. Westpac Banking Corp now owns 14,214 shares of the medical research company’s stock valued at $1,681,000 after buying an additional 1,691 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of Edwards Lifesciences by 41.9% in the second quarter. Principal Financial Group Inc. now owns 465,885 shares of the medical research company’s stock valued at $55,086,000 after buying an additional 137,643 shares in the last quarter. Institutional investors and hedge funds own 81.82% of the company’s stock.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $100.93, for a total transaction of $3,320,597.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Schack Wesley W. Von sold 1,000 shares of the stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $104.15, for a total transaction of $104,150.00. Following the sale, the director now owns 2,622 shares of the company’s stock, valued at $273,081.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,580 shares of company stock valued at $14,849,205. 2.13% of the stock is currently owned by corporate insiders.

Edwards Lifesciences declared that its board has authorized a share repurchase plan on Thursday, December 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/12/12/research-analysts-offer-predictions-for-edwards-lifesciences-corporations-q2-2018-earnings-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.